These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26417275)

  • 41. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
    Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
    Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
    Ji Y; Yin Y; Li Z; Zhang W
    Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD.
    Gart E; Souto Lima E; Schuren F; de Ruiter CGF; Attema J; Verschuren L; Keijer J; Salic K; Morrison MC; Kleemann R
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gut microbiota and metabolic syndrome.
    Festi D; Schiumerini R; Eusebi LH; Marasco G; Taddia M; Colecchia A
    World J Gastroenterol; 2014 Nov; 20(43):16079-94. PubMed ID: 25473159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
    Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
    Yang YJ; Ni YH
    J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
    Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
    Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease.
    Zhou J; Tripathi M; Sinha RA; Singh BK; Yen PM
    Hepatoma Res; 2021; 7():11. PubMed ID: 33490737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dietary lipids, gut microbiota and lipid metabolism.
    Schoeler M; Caesar R
    Rev Endocr Metab Disord; 2019 Dec; 20(4):461-472. PubMed ID: 31707624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'The way to a man's heart is through his gut microbiota'--dietary pro- and prebiotics for the management of cardiovascular risk.
    Tuohy KM; Fava F; Viola R
    Proc Nutr Soc; 2014 May; 73(2):172-85. PubMed ID: 24495527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.
    Jia W; Rajani C
    Adv Exp Med Biol; 2018; 1061():95-110. PubMed ID: 29956209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
    Koukias N; Buzzetti E; Tsochatzis EA
    Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 56. Microbiota, Obesity and NAFLD.
    Lau LHS; Wong SH
    Adv Exp Med Biol; 2018; 1061():111-125. PubMed ID: 29956210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota.
    Du F; Huang R; Lin D; Wang Y; Yang X; Huang X; Zheng B; Chen Z; Huang Y; Wang X; Chen F
    Front Microbiol; 2021; 12():611323. PubMed ID: 33708180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet.
    Machado MV; Cortez-Pinto H
    Int J Mol Sci; 2016 Apr; 17(4):481. PubMed ID: 27043550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role and effective therapeutic target of gut microbiota in NAFLD/NASH.
    Liu Q; Liu S; Chen L; Zhao Z; Du S; Dong Q; Xin Y; Xuan S
    Exp Ther Med; 2019 Sep; 18(3):1935-1944. PubMed ID: 31410156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.